Menu
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Buy Currently
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Sample Portfolio
Sample Portfolio Analysis
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Account Requirements
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
Municipal Bond Presentation
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Normally Buy
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF® Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Nurix Therapeutics, Inc. - Common stock
(NQ:
NRIX
)
12.94
+0.16 (+1.25%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 31, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Nurix Therapeutics, Inc. - Common stock
< Previous
1
2
3
4
5
Next >
The Daily Biotech Pulse: Pfizer Inks Pact With Africa For COVID-19 Pills, Emergent Bio & Ridgeback To Increase Access To Ebola Treatment, ADC Therapeutics & Sobi In European Pact For Lymphoma Drug
July 08, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
69 Biggest Movers From Friday
June 06, 2022
Gainers Turning Point Therapeutics, Inc. (NASDAQ: TPTX) shares climbed 118.4% to close at $74.59 on Friday after Bristol Myers Squibb announced it will acquire Turning Point Therapeutics for $76 per...
Via
Benzinga
Analyst Ratings for Nurix Therapeutics
May 27, 2022
Within the last quarter, Nurix Therapeutics (NASDAQ:NRIX) has observed the following analyst ratings:
Via
Benzinga
Stocks That Hit 52-Week Lows On Tuesday
January 18, 2022
Tuesday morning saw 454 companies set new 52-week lows. Interesting Facts About Today's 52-Week Lows: Unilever (NYSE:UL) was the largest firm by market cap to set a...
Via
Benzinga
40 Stocks Moving In Friday's Mid-Day Session
June 03, 2022
Gainers Turning Point Therapeutics, Inc. (NASDAQ: TPTX) shares jumped 115.8% to $73.72 after Bristol Myers Squibb announced it will acquire Turning Point Therapeutics for $76 per share.
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 31, 2022
May 31, 2022
Upgrades
Via
Benzinga
10 Biggest Price Target Changes For Friday
May 27, 2022
Keybanc boosted Broadcom Inc. (NASDAQ: AVGO) price target from $720 to $780. Broadcom shares rose 0.1% to $551.44 in pre-market trading.
Via
Benzinga
88 Biggest Movers From Yesterday
May 27, 2022
Gainers Creatd, Inc. (NASDAQ: CRTD) shares jumped 58.5% to close at $1.28 on Thursday. Creatd’s board approved a rights offering of up to $40 million for 20 million shares at $2 per unit.
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
May 26, 2022
Via
Benzinga
Stocks That Hit 52-Week Lows On Thursday
May 26, 2022
On Thursday, 94 companies set new 52-week lows.
Via
Benzinga
Nurix Therapeutics Doses First Patient in Phase 1a/1b Study of NX-5948 For B-cell malignancies
May 17, 2022
Nurix Therapeutics, Inc. (NASDAQ: NRIX) announced that the first patient has been dosed in the Phase 1a/1b study to evaluate orally available small molecule NX-5948, in patients with relapsed B-cell...
Via
Benzinga
Seagen CEO Clay Siegall Resigns After Domestic Violence Arrest
May 16, 2022
Clay Siegall and the board agreed it would be in investors' best interest if he resigned.
Via
Investor's Business Daily
61 Stocks Moving In Thursday's Mid-Day Session
May 26, 2022
Via
Benzinga
Nurix Therapeutics' BTK Programs Show Encouraging Preclinical Action In Blood Cancer, Solid Tumors
April 11, 2022
Nurix Therapeutics Inc (NASDAQ: NRIX) announced the
Via
Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
April 08, 2022
Gainers Phio Pharma (NASDAQ:PHIO) shares increased by 46.7% to $1.33 during Friday's regular session. As of 13:31 EST, Phio Pharma's stock is trading at a volume...
Via
Benzinga
Stocks That Hit 52-Week Lows On Friday
February 18, 2022
On Friday, 313 companies hit new 52-week lows. Things to Consider About Today's 52-Week Lows: The largest company in terms of market cap to set a new 52-week...
Via
Benzinga
Stocks That Hit 52-Week Lows On Thursday
February 17, 2022
On Thursday, 147 companies achieved new lows for the year. Significant Points From Today's 52-Week Lows: PayPal Holdings (NASDAQ:PYPL) was the biggest company...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 10, 2022
February 10, 2022
Upgrades According to Gordon Haskett, the prior rating for Williams-Sonoma Inc (NYSE:WSM) was changed from Hold to Accumulate. Williams-Sonoma earned $3.32 in the third quarter,...
Via
Benzinga
The Daily Biotech Pulse: Biogen Liquidates Out Of Biosimilar JV, Provention Bio Plots Diabetes Drug Resubmission, Merck Finds COVID Pill Effective Against Omicron
January 28, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Nurix Therapeutics: Q4 Earnings Insights
January 27, 2022
Nurix Therapeutics (NASDAQ:NRIX) reported its Q4 earnings results on Thursday, January 27, 2022 at 04:00 PM. Here's what investors need to know about the announcement....
Via
Benzinga
65 Biggest Movers From Yesterday
January 19, 2022
Gainers Brickell Biotech, Inc. (NASDAQ: BBI) shares jumped 58.6% to settle at $0.33 on Tuesday after HC Wainwright & Co initiated coverage on the stock with a Buy rating and...
Via
Benzinga
Wingstop, Akamai Initiations Among Today's Top Calls On Wall Street
December 29, 2021
Benchmark analyst Todd Brooks initiated coverage of Wingstop (WING) with a Hold rating and no price target. The analyst believes the stock's risk/reward is balanced at these levels given the current
Via
Talk Markets
60 Biggest Movers From Yesterday
January 11, 2022
Gainers Bone Biologics Corporation (NASDAQ: BBLG) shares surged 57.1% to close at $5.39 on Monday. Zynga Inc. (NASDAQ: ZNGA) rose 40.7% to settle at $8.44 after the company...
Via
Benzinga
Why Nurix Therapeutics Stock Soared More Than 21% Wednesday
October 27, 2021
The clinical-stage biopharmaceutical company posted positive news regarding its lead therapy -- a BTK inhibitor that could fight certain blood-based cancers.
Via
The Motley Fool
64 Biggest Movers From Yesterday
October 28, 2021
Gainers Siyata Mobile Inc. (NASDAQ: SYTA) shares jumped 83.4% to close at $5.30. Siyata Mobile released their Q2 earnings on an October 15th call that included CEO Marc...
Via
Benzinga
Why Did SVB Leerink Beef Up Target Price For Nurix Therapeutics?
October 27, 2021
SVB Leerink raised the price target on Nurix Therapeutics Inc (NASDAQ: NRIX) to $64 from $50, with an Outperform rating, seeing an upside of almost 92%. Analyst...
Via
Benzinga
Nurix Shares Gain On Encouraging Early Data From Blood Cancer Trial
October 27, 2021
Nurix Therapeutics Inc (NASDAQ: NRIX) announced initial data from Phase 1a trial of NX-2127 in relapsed or refractory B cell malignancies. Initial data from the...
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
October 27, 2021
Gainers Nurix Therapeutics (NASDAQ:NRIX) stock moved upwards by 15.4% to $33.42 during Wednesday's regular session. Trading volume for Nurix Therapeutics's stock...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 14, 2021
October 14, 2021
Upgrades According to Roth Capital, the prior rating for Ring Energy Inc (AMEX:
Via
Benzinga
Return on Capital Employed Insights for Nurix Therapeutics
July 29, 2021
After pulling data from Benzinga Pro it seems like during Q2, Nurix Therapeutics (NASDAQ:NRIX) brought in sales totaling $7.09 million. However, earnings decreased 7.72%,...
Via
Benzinga
< Previous
1
2
3
4
5
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.